Sydney E. Salmon, MD - Publications

Medicine/Oncology University of Arizona College of Medicine 
Chemotherapy, clinical trials

115 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2006 Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 929-36. PMID 16432076 DOI: 10.1200/Jco.2005.04.5807  0.352
2001 Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR, Munshi N, Crawford ED. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. The New England Journal of Medicine. 345: 1655-9. PMID 11759643 DOI: 10.1056/Nejmoa003013  0.324
2001 Taylor CW, Dorr RT, Fanta P, Hersh EM, Salmon SE. A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 47: 83-8. PMID 11221967 DOI: 10.1007/S002800000207  0.361
1998 Monk BJ, Alberts DS, Burger RA, Fanta PT, Hallum AV, Hatch KD, Salmon SE. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human cervical cancers Gynecologic Oncology. 71: 308-312. PMID 9826477 DOI: 10.1006/Gyno.1998.5140  0.42
1998 Miller TP, Chase EM, Dorr R, Dalton WS, Lam KS, Salmon SE. A phase I/II trial of paclitaxel for non-Hodgkin's lymphoma followed by paclitaxel plus quinine in drug-resistant disease. Anti-Cancer Drugs. 9: 135-40. PMID 9510499 DOI: 10.1097/00001813-199802000-00004  0.414
1998 Salmon SE, Crowley JJ, Balcerzak SP, Roach RW, Taylor SA, Rivkin SE, Samlowski W. Interferon versus interferon plus prednisone remission maintenance therapy for multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 16: 890-6. PMID 9508170 DOI: 10.1200/Jco.1998.16.3.890  0.356
1997 Alberts DS, Fanta PT, Running KL, Adair LP, Garcia DJ, Liu-Stevens R, Salmon SE. In vitro phase II comparison of the cytotoxicity of a novel platinum analog, nedaplatin (254-S), with that of cisplatin and carboplatin against fresh, human ovarian cancers Cancer Chemotherapy and Pharmacology. 39: 493-497. PMID 9118460 DOI: 10.1007/S002800050604  0.45
1997 Taylor CW, Dalton WS, Mosley K, Dorr RT, Salmon SE. Combination chemotherapy with cyclophosphamide, vincristine, adriamycin, and dexamethasone (CVAD) plus oral quinine and verapamil in patients with advanced breast cancer. Breast Cancer Research and Treatment. 42: 7-14. PMID 9116320 DOI: 10.1023/A:1005716214718  0.452
1997 Parza NZ, Taetle R, Nelson M, Adair T, Alberts D, Leong S, Salmon S, Krizman D, Thompson FG, Trent J. Chromosome instability in 75 untreated ovarian cancer patients Cancer Genetics and Cytogenetics. 98: 171. DOI: 10.1016/S0165-4608(97)90327-7  0.305
1997 Taetle R, Aickin M, Thompson F, Emerson J, Dalton W, Leong S, Bangert J, Bhattacharyya A, Weinstein R, Salmon S, Panda M, Trent J. Clinical cytogenetic correlations in solid tumors Cancer Genetics and Cytogenetics. 98: 151. DOI: 10.1016/S0165-4608(97)90248-X  0.329
1996 Lehnert M, de Giuli R, Kunke K, Emerson S, Dalton WS, Salmon SE. Serum can inhibit reversal of multidrug resistance by chemosensitisers. European Journal of Cancer (Oxford, England : 1990). 32: 862-7. PMID 9081367 DOI: 10.1016/0959-8049(96)00004-4  0.302
1996 Dorr RT, Dvorakova K, Snead K, Alberts DS, Salmon SE, Pettit GR. Antitumor activity of combretastatin-A4 phosphate, a natural product tubulin inhibitor. Investigational New Drugs. 14: 131-7. PMID 8913833 DOI: 10.1007/Bf00210783  0.338
1995 Salmon SE, Lam KS, Felder S, Yeoman H, Schlessinger J, Ullrich A, Krchnak V, Lebl M. Use of large combinatorial chemical libraries for anticancer drug discovery Pharmaceutical Biology. 33: 67-74. DOI: 10.3109/13880209509067089  0.302
1995 Taetle R, Thompson F, Trent J, Emerson J, Weinstein R, Leong S, Dalton W, Salmon S, Roe D, Alberts D. Clinical correlations of chromosome abnormalities in human breast, melanoma and ovarian cancer: preliminary analyses of 580 patients Cancer Genetics and Cytogenetics. 84: 135. DOI: 10.1016/0165-4608(96)85233-2  0.343
1994 Salmon SE, Hersh EM. Sensitivity of Multiple Myeloma to Imexon in the Human Tumor Cloning Assay Journal of the National Cancer Institute. 86: 228-230. PMID 8283495 DOI: 10.1093/Jnci/86.3.228  0.357
1994 Salmon SE, Crowley JJ, Grogan TM, Finley P, Pugh RP, Barlogie B. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: a Southwest Oncology Group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 12: 2405-14. PMID 7964957 DOI: 10.1200/Jco.1994.12.11.2405  0.391
1994 Barlogie B, Crowley J, Salmon SE, Bonnet J, Weick JK, Hayden K. Phase II study of carboplatin (CBDCA) in refractory multiple myeloma. A Southwest Oncology Group study. Investigational New Drugs. 12: 53-5. PMID 7960607 DOI: 10.1007/Bf00873237  0.451
1994 Salmon SE, Lam KS, Felder S, Yeoman H, Schlessinger J, Ullrich A, Krchnák V, Lebl M. One bead, one chemical compound: use of the selectide process for anticancer drug discovery. Acta Oncologica (Stockholm, Sweden). 33: 127-31. PMID 7911310 DOI: 10.3109/02841869409098395  0.302
1994 Gupta V, Thompson EB, Stock-Novack D, Salmon SE, Pierce HI, Bonnet JD, Chilton D, Beckford J. Efficacy of prednisone in refractory multiple myeloma and measurement of glucocorticoid receptors. A Southwest Oncology Group study. Investigational New Drugs. 12: 121-8. PMID 7860228 DOI: 10.1007/Bf00874441  0.394
1994 Federico M, Alberts DS, Garcia DJ, Emerson J, Fanta P, Liu R, Salmon SE. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome. Gynecologic Oncology. 55: S156-63. PMID 7835801 DOI: 10.1006/Gyno.1994.1356  0.458
1993 Emerson JC, Salmon SE, Dalton W, McGee DL, Yang JM, Thompson FH, Trent JM. Cytogenetics and clinical correlations in breast cancer. Advances in Experimental Medicine and Biology. 330: 107-18. PMID 8368128 DOI: 10.1007/978-1-4615-2926-2_9  0.387
1993 List AF, Spier C, Greer J, Wolff S, Hutter J, Dorr R, Salmon S, Futscher B, Baier M, Dalton W. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 11: 1652-60. PMID 8102639 DOI: 10.1200/Jco.1993.11.9.1652  0.302
1993 Grogan TM, Spier CM, Salmon SE, Matzner M, Rybski J, Weinstein RS, Scheper RJ, Dalton WS. P-glycoprotein expression in human plasma cell myeloma: correlation with prior chemotherapy Blood. 81: 490-495. DOI: 10.1182/Blood.V81.2.490.Bloodjournal812490  0.409
1993 Yang J, Thompson F, Knox S, Dalton W, Salmon S, Trent J. Polyclonal origin of a primary breast carcinoma demonstrated by serial cytogenetic studies of a patient with a history of osteosarcoma Cancer Genetics and Cytogenetics. 66: 153. DOI: 10.1016/0165-4608(93)90297-Y  0.313
1992 Alberts DS, Dorr RT, Wunz TP, Remers WA, Einspahr J, Liu R, Salmon SE. In vitro cytotoxicity against fresh human tumors and P388 leukemia predicts the differential in vivo activity of a series of anthracene anticancer drugs. Anti-Cancer Drugs. 2: 69-77. PMID 1958855 DOI: 10.1097/00001813-199102000-00010  0.409
1992 Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE. Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro. Journal of the National Cancer Institute. 84: 1238-44. PMID 1640482 DOI: 10.1093/Jnci/84.16.1238  0.376
1992 Taylor CW, Lui R, Fanta P, Salmon SE. Effects of Suramin on In Vitro Growth of Fresh Human Tumors Journal of the National Cancer Institute. 84: 489-494. PMID 1545438 DOI: 10.1093/Jnci/84.7.489  0.431
1992 Feo-Zuppardi FJ, Taylor CW, Iwato K, Lopez MHA, Grogan TM, Odeleye A, Hersh EM, Salmon SE. Long-term engraftment of fresh human myeloma cells in SCID mice. Blood. 80: 2843-2850. DOI: 10.1182/Blood.V80.11.2843.Bloodjournal80112843  0.313
1991 Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP, Salmon SE. Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. Journal of the National Cancer Institute. 83: 105-10. PMID 1988684 DOI: 10.1093/Jnci/83.2.105  0.338
1991 Lehnert M, Dalton WS, Roe D, Emerson S, Salmon SE. Synergistic inhibition by verapamil and quinine of P-glycoprotein-mediated multidrug resistance in a human myeloma cell line model. Blood. 77: 348-54. PMID 1670760 DOI: 10.1182/Blood.V77.2.348.Bloodjournal772348  0.355
1991 Miller TP, Grogan TM, Dalton WS, Spier CM, Scheper RJ, Salmon SE. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 9: 17-24. PMID 1670642 DOI: 10.1200/Jco.1991.9.1.17  0.404
1991 Burgess A, Thompson F, Olson S, Leong S, Salmon S, Trent J. Detailed description of abnormal cytogenetic findings in 32 patients with metastatic melanoma Cancer Genetics and Cytogenetics. 56: 122. DOI: 10.1016/0165-4608(91)90421-P  0.338
1991 Thompson F, Liu Y, Alberts D, Nahhas W, Salmon S, Trent J. Mosaicism for Turner's syndrome (45,X/46,XX) diagnosed after cytogenetic study of an ovarian tumor Cancer Genetics and Cytogenetics. 56: 113. DOI: 10.1016/0165-4608(91)90405-J  0.302
1990 Edelstein MB, Crowley JJ, Valeriote FA, Bonnet JD, Carden JO, Khanna RC, Salmon SE, Ungerleider JS. A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study. Investigational New Drugs. 8: S83-6. PMID 2380019 DOI: 10.1007/Bf00171990  0.389
1990 Taylor CW, Salmon SE, Satterlee WG, Robertone AB, McCloskey TM, Holdsworth MT, Plezia PM, Alberts DS. A phase I and pharmacokinetic study of intravenous vinzolidine. Investigational New Drugs. 8: S51-7. PMID 2380017 DOI: 10.1007/Bf00171984  0.401
1990 Trent JM, Meyskens FL, Salmon SE, Ryschon K, Leong SPL, Davis JR, McGee D. Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma New England Journal of Medicine. 322: 1508-1511. PMID 2336077 DOI: 10.1056/Nejm199005243222107  0.361
1990 Vaughn CB, Salmon SE, Fleming TR. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study. Investigational New Drugs. 8: 81-85. PMID 2188929 DOI: 10.1007/Bf00216929  0.373
1990 Karanes C, Crowley J, Sawkar L, Tranum BL, Hicks WJ, Bonnet JD, Dabich L, Dana BW, Salmon S. Aclacinomycin A in the treatment of multiple myeloma: a Southwest Oncology Group study. Investigational New Drugs. 8: 101-104. PMID 2188925 DOI: 10.1007/Bf00216933  0.37
1990 Salmon SE, Tesh D, Crowley J, Saeed S, Finley P, Milder MS, Hutchins LF, Coltman CA, Bonnet JD, Cheson B. Chemotherapy is superior to sequential hemibody irradiation for remission consolidation in multiple myeloma: a Southwest Oncology Group study. Journal of Clinical Oncology. 8: 1575-1584. PMID 2131793 DOI: 10.1200/Jco.1990.8.9.1575  0.37
1990 Scuderi P, Woo L, Chong AS-, Liu R, Salmon SE. Modification of the clonogenic assay for the detection of lymphokine activated killer cell activity. Journal of Immunological Methods. 128: 119-126. PMID 2109014 DOI: 10.1016/0022-1759(90)90470-G  0.376
1990 Kraut EH, Crowley JJ, Grever MR, Keppen MD, Bonnet JD, Hynes HE, Salmon SE. Phase II study of fludarabine phosphate in multiple myeloma. A Southwest Oncology Group study. Investigational New Drugs. 8: 199-200. PMID 1696569 DOI: 10.1007/Bf00177259  0.374
1990 Taylor C, Grogan T, Salmon S. Effects of interleukin-4 on the in vitro growth of human lymphoid and plasma cell neoplasms Blood. 75: 1114-1118. DOI: 10.1182/Blood.V75.5.1114.1114  0.361
1989 Dorr RT, Salmon SE, Robertone A, Bonnem E. Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days. Journal of Interferon Research. 8: 717-25. PMID 3230330 DOI: 10.1089/Jir.1988.8.717  0.385
1989 Sykes HF, Sim DA, Wong CJ, Robert Cassady J, Salmon SE. Local-regional recurrence in breast cancer after mastectomy and adriamycin-based adjuvant chemotherapy: Evaluation of the role of postoperative radiotherapy International Journal of Radiation Oncology, Biology, Physics. 16: 641-647. PMID 2921164 DOI: 10.1016/0360-3016(89)90479-3  0.386
1989 Salmon SE, Soehnlen B, Dalton WS, Meltzer P, Scuderi P. Effects of tumor necrosis factor on sensitive and multidrug resistant human leukemia and myeloma cell lines. Blood. 74: 1723-7. PMID 2790197 DOI: 10.1182/Blood.V74.5.1723.Bloodjournal7451723  0.327
1989 Charnetsky PS, Greisman RA, Salmon SE, Hersh EM, Scuderi P. Increased peripheral blood leukocyte cytotoxic activity in cancer patients during the continuous intravenous administration of recombinant human tumor necrosis factor. Journal of Clinical Immunology. 9: 34-38. PMID 2784796 DOI: 10.1007/Bf00917125  0.406
1989 Salmon SE, Liu R. Effects of granulocyte-macrophage colony-stimulating factor on in vitro growth of human solid tumors. Journal of Clinical Oncology. 7: 1346-1350. PMID 2671290 DOI: 10.1200/Jco.1989.7.9.1346  0.342
1989 Welander CE, Jones CM, Alberts DS, Salmon SE. In vitro sensitivity of human endometrial cancer to cytotoxic and biologic agents. Cancer Treatment and Research. 49: 117-126. PMID 2577199 DOI: 10.1007/978-1-4613-0867-6_9  0.415
1989 Salmon SE, Grogan TM, Miller T, Scheper R, Dalton WS. Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. Journal of the National Cancer Institute. 81: 696-701. PMID 2565403 DOI: 10.1093/Jnci/81.9.696  0.423
1989 Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE. Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 7: 415-24. PMID 2564428 DOI: 10.1200/Jco.1989.7.4.415  0.412
1989 Hersh EM, Scuderi P, Grimes WJ, Chong A, Brailey JL, Gschwind CR, Salmon SE. Cytostatic and cytotoxic activity of lymphokine-activated killer cell supernatants Cancer Immunology, Immunotherapy. 30: 65-70. PMID 2480843 DOI: 10.1007/Bf01665032  0.392
1989 Dalton WS, Grogan TM, Rybski JA, Scheper RJ, Richter L, Kailey J, Broxterman HJ, Pinedo HM, Salmon SE. Immunohistochemical detection and quantitation of p-glycoprotein in multiple drug-resistant human myeloma cells: association with level of drug resistance and drug accumulation Blood. 73: 747-752. DOI: 10.1182/Blood.V73.3.747.747  0.34
1987 Schwartz JE, Salmon SE. Comparative in vitro activity of 4'-deoxy-4'-iododoxorubicin and other anthracyclines in the human tumor clonogenic assay. Investigational New Drugs. 5: 231-234. PMID 3478322 DOI: 10.1007/Bf00175292  0.383
1987 Salmon SE, Young L, Scuderi P, Clark B. Antineoplastic effects of tumor necrosis factor alone and in combination with gamma-interferon on tumor biopsies in clonogenic assay. Journal of Clinical Oncology. 5: 1816-1821. PMID 3119787 DOI: 10.1200/Jco.1987.5.11.1816  0.403
1987 Tesh DW, Salmon SE. Role of sequential fractionated hemibody irradiation as consolidation folloowing induction chemotherapy for previously untreated patients with multiple myeloma International Journal of Radiation Oncology Biology Physics. 13: 153-154. DOI: 10.1016/0360-3016(87)91140-0  0.359
1986 Perrot LJ, Young L, Salmon SE. Identification of mesothelial cell clusters in agar cultures of effusions from patients with breast cancer. Stem Cells. 4: 69-70. PMID 3950457 DOI: 10.1002/Stem.5530040108  0.311
1986 Salmon SE. Human tumor clonogenic assays: growth conditions and applications Cancer Genetics and Cytogenetics. 19: 21-28. PMID 3940176 DOI: 10.1016/0165-4608(86)90367-5  0.398
1986 Braich TA, Salmon SE, Robertone A, Alberts DS, Jones SE, Miller TP, Garewal HS. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma. Investigational New Drugs. 4: 269-274. PMID 3818231 DOI: 10.1007/Bf00179595  0.388
1986 Braich T, Ahmann FR, Garewal HS, Robertone A, Salmon SE. Phase II trial of 4'-deoxydoxorubicin (esorubicin) in hormone resistant prostate cancer. Investigational New Drugs. 4: 193-196. PMID 3733379 DOI: 10.1007/Bf00194602  0.336
1986 Durie BG, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, Salmon SE, Dabich L, Files JC, Costanzi JJ. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. Journal of Clinical Oncology. 4: 1227-1237. PMID 3525768 DOI: 10.1200/Jco.1986.4.8.1227  0.372
1985 Perrot LJ, Salmon SE, Young L, Graham AR, Payne CM. Benign mediastinal teratoma with immature elements exhibited clonal growth and motility in the human tumor clonogenic assay International Journal of Cell Cloning. 3: 33-43. PMID 3973427 DOI: 10.1002/Stem.5530030106  0.362
1985 Salmon SE. In vitro assay for sensitivity to anticancer drugs. Hospital Practice. 20: 133-148. PMID 3924923 DOI: 10.1080/21548331.1985.11703079  0.435
1984 Salmon SE, Young L, Lebowitz J, Thomson S, Einsphar J, Tong T. Evaluation of an automated image analysis system for counting human tumor colonies Stem Cells. 2: 142-160. PMID 6736686 DOI: 10.1002/Stem.5530020301  0.39
1984 Ludwig R, Alberts DS, Miller TP, Salmon SE. Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay. Cancer Chemotherapy and Pharmacology. 12: 135-141. PMID 6705130 DOI: 10.1007/Bf00256533  0.4
1984 Garewal HS, Robertone A, Salmon SE, Jones SE, Alberts DS, Brooks R. Phase I trial of esorubicin (4'deoxydoxorubicin). Journal of Clinical Oncology. 2: 1034-1039. PMID 6470753 DOI: 10.1200/Jco.1984.2.9.1034  0.374
1984 Alberts DS, Einspahr JG, Struck R, Bignami G, Young L, Surwit EA, Salmon SE. Comparative in vitro cytotoxicity of cyclophosphamide, its major active metabolites and the new oxazaphosphorine ASTA Z 7557 (INN mafosfamide). Investigational New Drugs. 2: 141-148. PMID 6469507 DOI: 10.1007/Bf00232343  0.386
1984 Takasugi BJ, Salmon SE, Nelson RL, Young L, Liu RM. Antitumor activity of vinzolidine in the human tumor clonogenic assay and comparison with vinblastine. Investigational New Drugs. 2: 49-53. PMID 6469498 DOI: 10.1007/Bf00173786  0.397
1984 Ludwig CU, Peng YM, Beaudry JN, Salmon SE. Cytotoxicity of mitomycin C on clonogenic human carcinoma cells is not enhanced by hypoxia. Cancer Chemotherapy and Pharmacology. 12: 146-150. PMID 6423304 DOI: 10.1007/Bf00256535  0.354
1984 Meyskens FL, Loescher L, Moon TE, Takasugi B, Salmon SE. Relation of in vitro colony survival to clinical response in a prospective trial of single-agent chemotherapy for metastatic melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2: 1223-8. PMID 6387058 DOI: 10.1200/Jco.1984.2.11.1223  0.363
1984 Ludwig CU, Durie BGM, Salmon SE, Moon TE. Effect of Leukocyte Interferons on Cell Proliferation of Human Tumors In Vitro Recent Results in Cancer Research. 94: 220-223. PMID 6208584 DOI: 10.1007/978-3-642-82295-7_23  0.37
1984 Takasugi BJ, Robertone AB, Salmon SE, Jones SE, Alberts DS. Five-day schedule of vinzolidine, an oral vinca alkaloid, in a variety of tumors Investigational New Drugs. 2: 387-390. PMID 6096287 DOI: 10.1007/Bf00171590  0.559
1983 Jiang TL, Liu RH, Salmon SE. Antitumor activity of didemnin B in the human tumor stem cell assay. Cancer Chemotherapy and Pharmacology. 11: 1-4. PMID 6883622 DOI: 10.1007/Bf00257406  0.442
1983 Aapro MS, Alberts DS, Salmon SE. Interactions of human leukocyte interferon with vinca alkaloids and other chemotherapeutic agents against human tumors in clonogenic assay Cancer Chemotherapy and Pharmacology. 10: 161-166. PMID 6861260 DOI: 10.1007/Bf00255753  0.341
1983 Salmon SE, Alberts DS, Meyskens FL, Moon TE, Aapro MS, Eliason JR, Umbach GE, Spitzer G, Hug V, Atkinson EN, Plasse TF, Weisenthal LM, Balk S, Selby P, Buick R, et al. Human Tumor Stem-Cell Assay The New England Journal of Medicine. 308: 1478-1478. PMID 6855820 DOI: 10.1056/Nejm198306163082414  0.345
1983 Jiang T, Salmon SE, Liu RM. Activity of camptothecin, harringtonin, cantharidin and curcumae in the human tumor stem cell assay European Journal of Cancer and Clinical Oncology. 19: 263-270. PMID 6681771 DOI: 10.1016/0277-5379(83)90425-X  0.396
1983 Jiang TL, Liu RH, Salmon SE. Comparative in vitro antitumor activity of homoharringtonine and harringtonine against clonogenic human tumor cells Investigational New Drugs. 1: 21-25. PMID 6678854 DOI: 10.1007/Bf00180188  0.399
1983 Leibovitz A, Liu R, Hayes C, Salmon SE. A hypo‐osmotic medium to disaggregate tumor cell clumps into viable and clonogenic single cells for the human tumor stem cell clonogenic assay Stem Cells. 1: 478-485. PMID 6672110 DOI: 10.1002/Stem.5530010606  0.398
1983 Ludwig CU, Durie BGM, Salmon SE, Moon TE. Tumor growth stimulation in vitro by interferons. European Journal of Cancer and Clinical Oncology. 19: 1625-1632. PMID 6580172 DOI: 10.1016/0277-5379(83)90095-0  0.375
1983 Salmon SE, Liu R, Hayes C, Persaud J, Roberts R. Usefulness of abrin as a positive control for the human tumor clonogenic assay Investigational New Drugs. 1: 277-281. PMID 6432721 DOI: 10.1007/Bf00177410  0.379
1983 Pathak MA, Matrisian LM, Magun BE, Salmon SE. Effect of epidermal growth factor on clonogenic growth of primary human tumor cells. International Journal of Cancer. 30: 745-50. PMID 6298120 DOI: 10.1002/Ijc.2910300611  0.375
1983 Meyskens FL, Alberts DS, Salmon SE. Effect of 13‐cis‐retinoic acid and 4‐hydroxyphenyl‐all‐trans‐retinamide on human tumor colony formation in soft agar International Journal of Cancer. 32: 295-299. PMID 6224747 DOI: 10.1002/Ijc.2910320306  0.364
1983 Jones SE, Grozea PN, Metz EN, Haut A, Stephens RL, Morrison FS, Talley R, Butler JJ, Byrne GE, Hartsock R, Dixon D, Salmon SE. Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study. Cancer. 51: 1083-90. PMID 6185212 DOI: 10.1002/1097-0142(19830315)51:6<1083::Aid-Cncr2820510619>3.0.Co;2-M  0.564
1982 Stanisic TH, Buick RN, Trent JM, Fry SE, Salmon SE. An In Vitro Clonal Assay for Bladder Cancer: Studies of the Biologic Potential of the Urothelinm and Determination of In Vitro Sensitivity to Cytotoxic Agents The Journal of Urology. 127: 1043-1043. DOI: 10.1016/S0022-5347(17)54194-4  0.312
1981 Durie BGM, Cole PW, Chen H-G, Himmelstein KJ, Salmon SE. Synthesis and Metabolism of Bence Jones Protein and Calculation of Tumour Burden in Patients with Bence Jones Myeloma British Journal of Haematology. 47: 7-19. PMID 7437347 DOI: 10.1111/J.1365-2141.1981.Tb02757.X  0.31
1981 Alberts DS, Salmon SE, Chen HSG, Moon TE, Young L, Surwit EA. Pharmacologic studies of anticancer drugs with the human tumor stem cell assay Cancer Chemotherapy and Pharmacology. 6: 253-264. PMID 7318146 DOI: 10.1007/Bf00256978  0.371
1981 Moon TE, Salmon SE, White CS, Chen HG, Meyskens FL, Durie BGM, Alberts DS. Quantitative Association Between the in vitro Human Tumor Stem Cell Assay and Clinical Response to Cancer Chemotherapy Cancer Chemotherapy and Pharmacology. 6: 211-218. PMID 7318144 DOI: 10.1007/Bf00256973  0.414
1981 Trent JM, Salmon SE. Karyotypic analysis of human ovarian carcinoma cells cloned in short term agar culture Cancer Genetics and Cytogenetics. 3: 279-291. PMID 7260887 DOI: 10.1016/0165-4608(81)90037-6  0.314
1981 Alexanian R, Gutterman J, Dixon D, Salmon S, Bonnet J, Haut A. Chemoimmunotherapy for multiple myeloma Cancer. 47: 1923-1929. PMID 7226087 DOI: 10.1002/1097-0142(19810415)47:8<1923::Aid-Cncr2820470802>3.0.Co;2-Z  0.39
1981 Stanisic TH, Buick RN, Trent JM, Fry SE, Salmon SE. An in vitro clonal assay for bladder cancer: Studies of the biologic potential of the urothelium and determination of in vitro sensitivity to cytotoxic agents Journal of Surgical Oncology. 18: 67-72. PMID 7197316 DOI: 10.1002/Jso.2930180111  0.418
1981 Salmon SE, Liu RM, Casazza AM. Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemotherapy and Pharmacology. 6: 103-109. PMID 6946877 DOI: 10.1007/Bf00262325  0.397
1981 Meyskens FL, Salmon SE. Inhibition of human tumor colony formation by retinoids. Annals of the New York Academy of Sciences. 359: 414-414. PMID 6942692 DOI: 10.1111/J.1749-6632.1981.Tb12776.X  0.336
1981 Alberts DS, Chen HS, Salmon SE, Surwit EA, Young L, Moon TE, Meyskens FL. Chemotherapy of ovarian cancer directed by the human tumor stem cell assay Cancer Chemotherapy and Pharmacology. 6: 279-285. PMID 6172215 DOI: 10.1007/Bf00256981  0.441
1980 Buick RN, Fry SE, Salmon SE. Application of in vitro soft agar techniques for growth of tumor cells to the study of colon cancer Cancer. 45: 1238-1242. PMID 7357515 DOI: 10.1002/1097-0142(19800315)45:5+<1238::Aid-Cncr2820451333>3.0.Co;2-R  0.422
1980 Nash CH, Jones SE, Moon TE, Davis SL, Salmon SE. Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer. 46: 2380-2388. PMID 6449280 DOI: 10.1002/1097-0142(19801201)46:11<2380::Aid-Cncr2820461113>3.0.Co;2-M  0.53
1980 Alberts DS, Chen HSG, Soehnlen B, Salmon SE, Surwit EA, Young L, Moon TE. In-vitro clonogenic assay for predicting response of ovarian cancer to chemotherapy. The Lancet. 316: 340-342. PMID 6105478 DOI: 10.1016/S0140-6736(80)90340-2  0.418
1980 Trent JM, Salmon SE. Potential applications of a human tumor stem cell bioassay to the cytogenetic assessment of human cancer Cancer Genetics and Cytogenetics. 1: 291-296. DOI: 10.1016/0165-4608(80)90026-6  0.381
1979 Rainey JM, Jones SE, Salmon SE. Combination chemotherapy for advanced breast cancer utilizing vincristine, adriamycin, and cyclophosphamide (VAC) Cancer. 43: 66-71. PMID 761176 DOI: 10.1002/1097-0142(197901)43:1<66::Aid-Cncr2820430109>3.0.Co;2-1  0.559
1979 Hamburger AW, Kim MB, Salmon SE. The nature of cells generating human myeloma colonies in vitro. Journal of Cellular Physiology. 98: 371-376. PMID 422663 DOI: 10.1002/Jcp.1040980213  0.309
1979 Salmon SE, Jones SE. Studies of the combination of adriamycin and cyclophosphamide (Alone or with other agents) for the treatment of breast cancer Oncology (Switzerland). 36: 40-47. PMID 156337 DOI: 10.1159/000225316  0.56
1979 Lloyd RE, Jones SE, Salmon SE. Comparative trial of low-dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer. Cancer. 43: 60-65. PMID 153787 DOI: 10.1002/1097-0142(197901)43:1<60::Aid-Cncr2820430108>3.0.Co;2-M  0.556
1978 Hammond N, Jones SE, Salmon SE, Patton D, Woolfenden J. Predictive value of bone scans in an adjuvant breast cancer program. Cancer. 41: 138-142. PMID 626924 DOI: 10.1002/1097-0142(197801)41:1<138::Aid-Cncr2820410122>3.0.Co;2-6  0.526
1978 Cole PW, Durie BGM, Salmon SE. Immunoquantitation of free light chain immunoglobulins: Applications in multiple myeloma☆ Journal of Immunological Methods. 19: 341-349. PMID 416145 DOI: 10.1016/0022-1759(78)90018-2  0.337
1978 Salmon SE, Hamburger AW, Soehnlen B, Durie BGM, Alberts DS, Moon TE. Quantitation of Differential Sensitivity of Human-Tumor Stem Cells to Anticancer Drugs The New England Journal of Medicine. 298: 1321-1327. PMID 77475 DOI: 10.1056/Nejm197806152982401  0.439
1977 O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B. Dose response evaluation of adriamycin in human neoplasia Cancer. 39: 1940-1948. PMID 858124 DOI: 10.1002/1097-0142(197705)39:5<1940::Aid-Cncr2820390505>3.0.Co;2-0  0.308
1977 Alexanian R, Salmon S, Bonnet J, Gehan E, Haut A, Weick J. Combination therapy for multiple myeloma. Cancer. 40: 2765-71. PMID 589554 DOI: 10.1002/1097-0142(197712)40:6<2765::Aid-Cncr2820400602>3.0.Co;2-X  0.407
1977 Hamburger A, Salmon SE. Primary Bioassay of Human Myeloma Stem Cells Journal of Clinical Investigation. 60: 846-854. PMID 302265 DOI: 10.1172/Jci108839  0.364
1976 Jones SE, Salmon SE. The role of radionuclides in clinical oncology Seminars in Nuclear Medicine. 6: 331-346. PMID 62399 DOI: 10.1016/S0001-2998(76)80012-8  0.557
1975 Jones SE, Durie BGM, Salmon SE. Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer. 36: 90-97. PMID 1203853 DOI: 10.1002/1097-0142(197507)36:1<90::Aid-Cncr2820360104>3.0.Co;2-H  0.568
1975 Durie BGM, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 36: 842-854. PMID 1182674 DOI: 10.1002/1097-0142(197509)36:3<842::Aid-Cncr2820360303>3.0.Co;2-U  0.354
1975 Russell DH, Durie BGM, Salmon SE. Polyamines as predictors of success and failure in cancer chemotherapy. The Lancet. 306: 797-799. PMID 78158 DOI: 10.1016/S0140-6736(75)80009-2  0.357
1975 McMahon LJ, Jones SE, Durie BGM, Salmon SE. Combination chemotherapy with methyl-CCNU (NSC-95441), cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and bleomycin (NSC-125066) in advanced bronchogenic carcinoma Cancer Letters. 1: 97-101. PMID 65213 DOI: 10.1016/S0304-3835(75)95630-X  0.573
1975 Lilien DL, Jones SE, O'Mara RE, Salmon SE, Durie BGM. A clinical evaluation of indium-111 bleomycin as a tumor-imaging agent. Cancer. 35: 1036-1049. PMID 46776 DOI: 10.1002/1097-0142(197504)35:4<1036::Aid-Cncr2820350405>3.0.Co;2-2  0.568
1975 Salmon S. Expansion of the growth fraction in multiple myeloma with alkylating agents Blood. 45: 119-129. DOI: 10.1182/Blood.V45.1.119.Bloodjournal451119  0.434
1975 Salmon SE, Durie BGM. Cellular kinetics in multiple myeloma. A new approach to staging and treatment. Jama Internal Medicine. 135: 131-138. DOI: 10.1001/Archinte.1975.00330010133017  0.423
1973 Jones SE, Durie BGM, Salmon SE. Immunologic Aspects of the Hematologic Neoplasms Postgraduate Medicine. 54: 209-216. PMID 27393023 DOI: 10.1080/00325481.1973.11713622  0.547
Show low-probability matches.